Company Growth (employees)
Ultragenyx Pharmaceutical was founded in 2010 and is headquartered in Novato, US
Ultragenyx Pharmaceutical Office Locations
Ultragenyx Pharmaceutical has an office in Novato
Novato, US (HQ)
60 Leveroni Ct
Ultragenyx Pharmaceutical Data and Metrics
Ultragenyx Pharmaceutical Financial Metrics
Ultragenyx Pharmaceutical's revenue was reported to be $133 k in FY, 2016
USD
Net income (Q1, 2017) | (68.3 m) |
EBIT (Q1, 2017) | (70 m) |
Market capitalization (17-Aug-2017) | 2.5 b |
Cash (31-Mar-2017) | 159.5 m |
Ultragenyx Pharmaceutical's current market capitalization is $2.5 b.
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Revenue | 133 k | ||
R&D expense | 46 m | 114.7 m | 183.2 m |
General and administrative expense | 10.8 m | 33 m | 64.9 m |
Operating expense total | 56.8 m | 147.7 m | 248.1 m |
EBIT | (56.8 m) | (147.7 m) | (248 m) |
EBIT margin, % | (186471%) | ||
Interest income | 608 k | 2.3 m | 3.8 m |
Pre tax profit | (245.8 m) | ||
Income tax expense | (35 k) | ||
Net Income | (59.8 m) | (145.6 m) | (245.9 m) |
| USD | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|
Revenue | 17 k | 111 k | |||||
R&D expense | 17.4 m | 23.1 m | 29.7 m | 40.4 m | 43.3 m | 48.7 m | 51.3 m |
General and administrative expense | 4.1 m | 7 m | 10.2 m | 13.2 m | 14.7 m | 17.2 m | 18.7 m |
Operating expense total | 21.5 m | 30.1 m | 39.9 m | 53.6 m | 58.1 m | 65.9 m | 70 m |
EBIT | (21.5 m) | (30.1 m) | (39.9 m) | (53.6 m) | (58.1 m) | (65.8 m) | (70 m) |
EBIT margin, % | (341488%) | (59264%) | |||||
Interest income | 273 k | 456 k | 673 k | 984 k | 971 k | 922 k | 1.1 m |
Net Income | (21.4 m) | (29.8 m) | (39.2 m) | (52.8 m) | (56.9 m) | (64.9 m) | (68.3 m) |
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Cash | 24.3 m | 93.6 m | 161.1 m |
Inventories | 5.9 m | 13.1 m | 20.1 m |
Current Assets | 193.4 m | 450.2 m | 401.7 m |
PP&E | 3 m | 7.4 m | 17.1 m |
Total Assets | 198 m | 559.6 m | 540.6 m |
Accounts Payable | 4.9 m | 2.9 m | 5.4 m |
Current Liabilities | 12.5 m | 27.9 m | 60.3 m |
Total Liabilities | 66.7 m | ||
Additional Paid-in Capital | 324.1 m | 816.6 m | 1 b |
Retained Earnings | (139 m) | (284.7 m) | (530.5 m) |
Total Equity | 531.1 m | 474 m | |
Financial Leverage | 1.1 x | 1.1 x |
| USD | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|
Cash | 178 m | 52.4 m | 166.7 m | 70.8 m | 55.1 m | 142.3 m | 159.5 m |
Current Assets | 350.5 m | 336.5 m | 460.7 m | 430.2 m | 411.1 m | 416.8 m | 444.7 m |
PP&E | 3.5 m | 4.8 m | 6.3 m | 13.4 m | 17.1 m | 18.2 m | 16.5 m |
Total Assets | 355.8 m | 343 m | 602.1 m | 524.2 m | 482 m | 515.2 m | 545.8 m |
Accounts Payable | 5.8 m | 10.2 m | 4.4 m | 6 m | 7 m | 6.6 m | 8.3 m |
Current Liabilities | 14.2 m | 23 m | 24.7 m | 29.9 m | 32 m | 50.4 m | 51.8 m |
Additional Paid-in Capital | 501.6 m | 509.7 m | 806.2 m | 827.1 m | 837.9 m | 915.1 m | 1.1 b |
Retained Earnings | (160.4 m) | (190.2 m) | (229.4 m) | (337.4 m) | (394.3 m) | (459.2 m) | (598.8 m) |
Total Equity | 319.3 m | 576.8 m | 489.8 m | 443.9 m | 455.9 m | 488.5 m | |
Financial Leverage | 1.1 x | 1 x | 1.1 x | 1.1 x | 1.1 x | 1.1 x |
| USD | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|
Net Income | (59.8 m) | (145.6 m) | (245.9 m) |
Depreciation and Amortization | 684 k | 1.4 m | 3.4 m |
Inventories | (4.1 m) | (7.1 m) | (7.1 m) |
Accounts Payable | 3.2 m | (2 m) | 2.5 m |
Cash From Operating Activities | (44.6 m) | (106 m) | (161 m) |
Purchases of PP&E | (2.1 m) | (5 m) | (10.2 m) |
Cash From Investing Activities | (123.4 m) | (292.4 m) | 89.9 m |
Cash From Financing Activities | 185 m | 467.6 m | 138.7 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (21.4 m) | (29.8 m) | (39.2 m) | (52.8 m) | (56.9 m) | (64.9 m) | (68.3 m) | ||
Accounts Payable | 3.6 m | 4.2 m | 5.8 m | 10.2 m | 4.4 m | 6 m | 7 m | 6.6 m | 8.3 m |
| Y, 2017 | |
|---|---|
Financial Leverage | 1.1 x |
